Literature DB >> 28221265

Acute Liver Failure During Deferasirox Chelation: A Toxicity Worth Considering.

Nathan Menaker1, Katharine Halligan, Natasha Shur, John Paige, Matthew Hickling, Anne Nepo, Lauren Weintraub.   

Abstract

This case report details a unique case of acute, reversible liver failure in a 12-year-old male with sickle cell anemia on chronic transfusion protocol and deferasirox chelation. There is substantial literature documenting deferasirox-induced renal injury, including Fanconi syndrome, but less documentation of hepatic toxicity and few reports of hepatic failure. The case highlights the importance of close monitoring of ferritin, bilirubin, and transaminases for patients on deferasirox.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28221265     DOI: 10.1097/MPH.0000000000000786

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

1.  Significant Hyperbilirubinemia and Acute Hepatocellular Jaundice in a Pediatric Patient Receiving Deferasirox: A Case Report.

Authors:  Elizabeth A Feldman; Christopher D Miller; Sarabeth Wojnowicz; Robert Seabury
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jan-Feb

2.  Deferasirox-induced liver injury and Fanconi syndrome in a beta-thalassemia major male.

Authors:  Jacqueline Fraser; Rowena Brook; Tony He; Diana Lewis
Journal:  BMJ Case Rep       Date:  2020-07-09

3.  The iron chelator Deferasirox causes severe mitochondrial swelling without depolarization due to a specific effect on inner membrane permeability.

Authors:  Esther M Gottwald; Claus D Schuh; Patrick Drücker; Dominik Haenni; Adam Pearson; Susan Ghazi; Milica Bugarski; Marcello Polesel; Michael Duss; Ehud M Landau; Andres Kaech; Urs Ziegler; Anne K M Lundby; Carsten Lundby; Petra S Dittrich; Andrew M Hall
Journal:  Sci Rep       Date:  2020-01-31       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.